Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benzoyl peroxide/tretinoin - Sol-Gel Technologies

Next Previous
Drug Profile

Benzoyl peroxide/tretinoin - Sol-Gel Technologies

Alternative Names: Microencapsulated benzoyl peroxide 3% and microencapsulated tretinoin 0.1% cream; S6G5T 1/S6G5T 3; Tretinoin/benzoyl-peroxide; TWIN; Twyneo

Latest Information Update: 24 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sol-Gel Technologies
  • Developer Searchlight Pharma; Sol-Gel Technologies
  • Class Anti-infectives; Antiacnes; Benzoic acids; Keratolytics; Oxidants; Peroxides; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 17 Apr 2025 Benzoyl peroxide/tretinoin licensed to Mayne Pharma in USA
  • 17 Apr 2025 Sol-Gel mutually terminates licensing agreement with Galderma for benzoyl peroxide/tretinoin in USA, before April 2025
  • 30 Sep 2024 Preregistration for Acne vulgaris (In adolescents, In children, In adults, In the elderly) in Canada (Topical)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top